GLGordon Loewen

Gordon Loewen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gordon Loewen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules

    by Peter A. LeWitt, Olga Klepitskaya, Kurt Olson, Grace Liang, Gordon Loewen

    Objective: Both a catechol-O-methyltransferase inhibitor and extended-release (ER) levodopa formulations may enhance levodopa treatment through a more continuous levodopa delivery to the striatum; the combination of these therapies has not undergone a pharmacokinetic study. We evaluated the effects of once-daily opicapone 50 mg on levodopa plasma pharmacokinetics when added to a carbidopa/levodopa (CD/LD)-ER formulation (RYTARY ® ). Materials and Methods: This was an exploratory, open-label study of levodopa’s pharmacokinetics measured over 24 hours in healthy adults. Enrolled individuals received CD/LD-ER three times daily (TID) alone for 3 days, followed by once-daily opicapone for 14 days. On the last 3 days of the opicapone regimen, participants received CD/LD ER TID again. Pharmacokinetic parameters were evaluated after the 3-day exposure to CD/LD-ER alone and with concomitant administration of opicapone. Results: Eighteen healthy adults (9 male, 9 female) entered and completed the study. Levodopa exposure (area under the time-concentration curve) was higher with opicapone than with CD/LD-ER alone across all dosing intervals, including between 21:00 and 07:00 (10801.5 vs. 5153.3 ng/mL·h). Over 24 hours, mean levodopa trough concentration (C trough ) was higher with opicapone versus CD/LD-ER alone (677.2 vs. 266.8 ng/mL), as was minimum C trough (302.9 vs. 41.3 ng/mL). There was a greater increase in C trough (208%) than in maximum plasma concentration (75%), decreasing the fluctuation index by 38%. Conclusions: Adding opicapone to CD/LD-ER enhanced levodopa pharmacokinetics in healthy adults, by increasing levodopa trough levels. Notably, opicapone increased overnight and morning levodopa concentrations and decreased daily levodopa concentrations, sub-therapeutic for Parkinson disease patients.

  • Open Access

    Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa

    by Peter LeWitt, Grace S. Liang, C. Warren Olanow, Karl D. Kieburtz, Roland Ba Jimenez, Kurt Olson, Olga Md Klepitskaya, Gordon Loewen

    Objectives: Levodopa (LD) administered with dopa decarboxylase inhibitor is predominantly metabolized in the periphery by catechol-O-methyltransferase (COMT) to 3-O-methyldopa (3-OMD). Catechol-O-methyltransferase inhibition can improve treatment outcomes by decreasing variability in circulating LD concentrations. Opicapone is a once-daily COMT inhibitor approved in the US adjunctive to carbidopa (CD)/LD in patients with Parkinson disease experiencing “OFF” episodes. This study aimed to evaluate the pharmacokinetics and pharmacodynamics of once-daily opicapone 50 mg adjunctive to CD/LD in patients with stable Parkinson disease. Methods: Once-daily opicapone 50 mg was administered the evenings of days 1 to 14. Participants were randomized to receive CD/LD (25/100 mg) every 3 or 4 hours (Q3H or Q4H). Participants received Q3H or Q4H CD/LD on days 1, 2, and 15 and their usual CD/LD regimen on other days. Serial blood samples were collected to determine plasma opicapone, LD, and 3-OMD concentrations and erythrocyte soluble COMT (S-COMT) activity. The effects of opicapone on S-COMT, LD, and 3-OMD were assessed. Mean (SD) values are presented. Results: Sixteen participants were enrolled. At steady-state (day 14), opicapone C max (peak plasma concentration) and AUC0-last (area under the curve-time curve) were 459 ± 252 ng/mL and 2022 ± 783 ng/mL·h, respectively. Maximum COMT inhibition was 83.4 ± 4.9% of baseline on day 14. After opicapone administration, LD total AUC, peak concentration, and trough concentration increased; peak-to-trough fluctuation index decreased. Correspondingly, 3-OMD total AUC, peak concentration, and trough concentration decreased. Conclusions: Adding once-daily opicapone 50 mg to LD resulted in marked and extended COMT inhibition, which increased systemic exposure to LD. These changes translated into higher trough concentrations and decreased peak-to-trough fluctuations for LD.